SCHEMBL23728465

SCHEMBL23728465

CCOC(=O)c1cnn2ccc(OC)nc12

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 3/20 0.49
KDM4E B2RXH2 5/20 0.49
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
ALDH1A1 P00352 7/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
HPGD P15428 4/20 0.46
HSD17B10 Q99714 3/20 0.46
PDE2A O00408 1/20 0.45
PDE4B Q07343 1/20 0.44
TSHR P16473 3/20 0.42
PDE10A Q9Y233 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CSNK1D P48730 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16718827 0.85 TGFBR1 (0.50) TGFBR1KDM4ERAB9ANPC1ALDH1A1
SCHEMBL10204204 0.85 PDE2A (0.53) TGFBR1KDM4ERAB9ANPC1ALDH1A1
SCHEMBL22762873 0.84 ALDH1A1 (0.44) TGFBR1KDM4ERAB9ANPC1ALDH1A1
SCHEMBL461752 0.84 TGFBR1 (0.51) TGFBR1KDM4ERAB9ANPC1ALDH1A1
SCHEMBL18208131 0.83 TDP1 (0.49) TGFBR1KDM4EALDH1A1PDE2APDE4B
SCHEMBL402500 0.83 TGFBR1 (0.50) TGFBR1KDM4ERAB9ANPC1ALDH1A1
SCHEMBL22763214 0.83 KDM4E (0.53) TGFBR1KDM4ERAB9ANPC1ALDH1A1
SCHEMBL25162502 0.83 TGFBR1 (0.50) TGFBR1KDM4ERAB9ANPC1ALDH1A1
SCHEMBL18208219 0.82 SMPD3 (0.54) TGFBR1KDM4ERAB9ANPC1ALDH1A1
SCHEMBL30864204 0.81 KDM4E (0.52) TGFBR1KDM4ERAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TGFBR1 1014/4885KDM4E 190/4885RAB9A 4270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.